Deng et al. discovered that the anti-tumoral activity of p53 acts by downregulating ASNS expression to limit Asn synthesis in CRC, interrupting Asn-Asp equilibrium in vivo and in vitro (Deng et al., 2020). This evidence concerns the gene TP53 and colorectal carcinoma.